Access
Home
Search
Monetization
Profile
Antiviral Drugs Market Size, Share, Regional Sales, Growth, Industry Trends | Forecast 2026
Your avatar
NE
by
Neha
Your avatar
NE
by
Neha
Antiviral Drugs Market Size, Share, Regional Sales, Growth, Industry Trends | Forecast 2026

The Global Antiviral Drugs Market is set to gain impetus from the improvements in research collaborations of industry giants to develop state-of-the-art therapeutics. Besides, the increasing prevalence of viral diseases would impact the market positively. Fortune Business Insights™ published this information in a recent study, titled, “Antiviral Drugs Market Size, Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2019-2026.” The study further mentions that the antiviral drugs market size is projected to reach USD 44.2 billion by 2026, thereby exhibiting a CAGR of 3.2% during the forecast period. However, it stood at USD 36.1 billion in 2018.

For more information in the analysis of this report, visit:https://www.fortunebusinessinsights.com/antiviral-drugs-market-102190

Highlights of the Report

Extensive analysis of the antiviral drugs market trends, growth drivers, hindrances, opportunities, and challenges.

Profiles of the key organizations and their business strategies.

Quantitative analysis from 2019 to 2026 to help the stakeholders in capitalizing on the existing opportunities.

Detailed information about every possible segment present in the market.

Fortune Business Insights™ profiles some of the most prominent companies operating in the antiviral drugs market. They are as follows:

Abbvie, Inc.

Novartis AG

Gilead Sciences

Mylan N.V.

GlaxoSmithKline

Merck & Co., Inc.

Janssen Pharmaceuticals, Inc.

Bristol-Myers Squibb Company

Other key market players

High Demand for Targeted & Specific Treatment Regimen to Boost Growth

One of the most common forms of viral infection that is occurring across the world is HIV. The diagnosis rate of HIV is improving gradually owing to the refinement of surveillance by using biological and demographic data. The World Health Organization (WHO) stated that in the year 2018, approximately 37.9 million people were affected by HIV. However, around 770,000 people died of this disease. It proves that the rising cases of HIV is fueling the demand for specific and targeted treatment regimen. Apart from that, the rising prevalence of influenza and its efficient diagnosis are set to drive the antiviral drugs market growth in the coming years.

Request a Sample Copy of the Global Antiviral Drugs Market Research Report:https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/antiviral-drugs-market-102190

Study by FSU Aid in Battling HIV & Hepatitis B; Gilead Submits sNDA Application to FDA

Key enterprises present in the market are constantly striving to bring about new treatment options for the patients suffering from viral infections. They are aiming to gain the maximum antiviral drugs market share by bagging FDA approvals to broaden product portfolio. Educational institutions are also actively participating in conducting studies to discover new drugs. Below are two of the latest industry developments:

January 2020: The researchers of Florida State University (FSU) are set to open new doors for innovative treatment options for more than 36 million HIV-infected people across the globe. The new treatment options would also help treating the chronically ill patients with hepatitis B. For the first time, their work has established the mechanism accountable for how two antiviral drugs inhibit viruses.

April 2019: Gilead Sciences, Inc., a biotechnology company that researches, develops, and commercializes drugs, based in California, announced its submission of a supplemental New Drug Application (sNDA) to the FDA. It was done for its emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets called Descovy for pre-exposure prophylaxis (PrEP) to prevent sexually transmitted HIV-1 infection in those who are at risk.

 TOC of Antiviral Drugs Market:

Introduction

Research Scope

Market Segmentation

Research Methodology

Definitions and Assumptions

Executive Summary

Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Key Insights

Key Industry Trends

Recent industry developments such as mergers & acquisitions

regulatory and reimbursement scenario for key countries

Prevalence of Key viral diseases, in major countries, 2018

New Product Launches

Global Antiviral Drugs Market Analysis, Insights and Forecast, 2015-2026

Key Findings / Summary

Market Analysis, Insights and Forecast – By Disease Indication

Hepatitis

Human Immunodeficiency Virus (HIV)

Influenza

Others

Market Analysis, Insights and Forecast – By Drug Class

Integrase Inhibitors

Polymerase Inhibitors

Protease Inhibitors

Combination Drugs

Reverse Transcriptase Inhibitors

Others

Market Analysis, Insights and Forecast – By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Channel

Market Analysis, Insights and Forecast – By Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

North America Antiviral Drugs Market Analysis, Insights and Forecast, 2015-2026

Key Findings / Summary

Market Analysis – By Disease Indication

Hepatitis

Human Immunodeficiency Virus (HIV)

Influenza

Others

Market Analysis – By Drug Class

Integrase Inhibitors

Polymerase Inhibitors

Protease Inhibitors

Combination Drugs

Reverse Transcriptase Inhibitors

Others

Market Analysis – By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Channel

Market Analysis – By Country

U.S.

Canada

Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2015-2026

Key Findings / Summary

Market Analysis – By Disease Indication

Hepatitis

Human Immunodeficiency Virus (HIV)

Influenza

Others

Market Analysis – By Drug Class

Integrase Inhibitors

Polymerase Inhibitors

Protease Inhibitors

Combination Drugs

Reverse Transcriptase Inhibitors

Others

Market Analysis – By Distribution Channel

Hospital Pharmacy

Retail Pharmacy

Online Channel

Market Analysis – By Country/Sub-region

U.K.

Germany

France

Spain

Italy

Scandinavia

Rest of Europe

Have Any Query? Ask Our Experts:https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/antiviral-drugs-market-102190

About Us:

Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data. 

At Fortune Business Insights™, we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Contact Us:

Fortune Business Insights™ Pvt. Ltd.

308, Supreme Headquarters,

Survey No. 36, Baner,

Pune-Bangalore Highway,

Pune - 411045, Maharashtra, India.

Phone:

US: +1 424 253 0390

UK: +44 2071 939123

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Size
0.00€
Cheer up, leave your comment
0
If you liked this post, you may also be interested in...
O
© 2021, Mamby Investments
Information Work with us Terms and Conditions Contact FAQs